PFE
Pfizer, Inc.Close $25.66EOD onlyThis page reflects PFE options positioning from the latest published market-close snapshot. Intraday price and contract changes are not displayed.
Historical consensus-supported lens with full content, report chain context, and metric rail.
Outlook
Bullish with a pinning bias toward $27-$28. Confidence: 7/10. Strong positive GEX ($222.9M) and bullish flow (P/C vol 0.40) support upside, but spot is 6% above the nearest max pain, creating a short-term gravitational pull lower.
Conflicts: Spot ($28.08) is above nearest max pain ($26.50 for 3/27), suggesting a potential drift lower to meet pinning gravity.
Regime Classification
Price Range Forecast
Key Levels
Dealer Positioning (GEX/DEX)
GEX: $+222.9M
DEX: +70.2M shares
Gamma flip: ~$20 (Approx — based on put OI concentration of 60,221)
NTM gamma: Dealers are **net long $222.9M gamma**, strongest near $27-$28 strikes. A move **+2% to ~$28.65** increases pinning pressure. A move **-2% to ~$27.50** likely sees accelerated dealer buying (long gamma), providing a cushion.
IV Analysis
IV vs VIX: IV 29.0% — No VIX provided for direct comparison, but term structure shows no extreme richness or cheapness.
Term structure: **Humped with a kink at 5/08 (38 DTE, IV 33.2%).** This is likely pricing the 5/05 earnings event. IV drops sharply after (29.1% for 5/15).
Skew: **~7 vol-point differential between 5/08 (33.2%) and 5/15 (29.1%)** — supports a post-earnings vol crush calendar spread (sell May 8, buy May 15).
Flow Analysis
Net premium: +$6.3M bullish; P/C vol 0.40 (extreme call skew), P/C OI 0.82.
Directional prints: $28C saw $1.54M net premium (Vol 3.6k vs OI 45k) — likely **bought calls** for upside. $30.50C 4/17 saw 966 vol vs 203 OI (4.8x) at low IV (23.6%) — could be bullish speculation or a covered call roll. Interpretation: Bullish flow is more consistent with the regime.
Unusual: $29P 5/15 saw 463 vol vs 290 OI (1.6x) at elevated IV (30.9%) — could be a protective put buy or premium sale. Given high IV and earnings proximity, selling is more likely.
Risks & Catalysts
Strategy Viability
| Strategy | Edge | Best Setup | Primary Risk |
|---|---|---|---|
| Long Stock | Moderate-Strong | Buy shares at market (~$28.08). | Pullback to max pain ($26.50); sector/macro downturn. |
| Short Stock | Weak | N/A | Contravenes strong bullish flow and positive GEX; only viable on a break below $25. |
| Covered Call | Moderate-Strong | Own shares, sell $30C 5/15 (45 DTE) for ~$0.45. | Shares rally past $30, capping upside. |
| Cash-Secured Put / Put Spread | Moderate-Strong | Sell $27/$26 put spread 4/17 (17 DTE) for ~$0.30 credit. | Spot breaks below $27 support. |
| Long Calls | Moderate | Buy $28C 5/15 (45 DTE) for ~$1.10. | Time decay and pullback to max pain; IV is not low. |
| Long Puts / Bear Put Spread | Moderate-Weak | Buy $28/$27 put spread 4/10 (10 DTE) for ~$0.40 debit. | Strong bullish flow and pinning make sustained downside difficult. |
| Iron Condor | Strong | $27/$26P x $29/$30C 4/17 (17 DTE). | Earnings vol spike in early May; break of EM bounds. |
| Calendar/Diagonal | Moderate | **Reverse Calendar:** Sell $30C 5/08 (33.2% IV), Buy $30C 5/15 (29.1% IV) for a net credit. | Spot moves far from $30, killing theta decay; pin risk. |
| PMCC / LEAPS Diagonal | Moderate-Strong | Buy $25C 12/18 (262 DTE, ~$4.50), Sell $30C 5/15 (45 DTE) against it. | Capital intensive; long-dated IV decay if thesis fails. |
Top Plays
Watchlist Triggers
Tactical Summary
Each report translates the same market-close options snapshot into a specific lens such as directional bias, premium-selling posture, flow quality, or earnings setup.
Reports are most useful for narrowing the playbook, surfacing entry and risk context, and deciding which raw data page to inspect next.
These are interpretation layers, not execution guarantees. Validate the setup against chain liquidity, expected move, and exposure before sizing risk.